查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771735

美國原料藥CDMO 市場規模、佔有率和趨勢分析報告：按產品、合成、藥物、工作流程、應用和細分市場預測，2025 年至 2030 年

U.S. Active Pharmaceutical Ingredients CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, ADC), By Synthesis, By Drug, By Workflow, By Application, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

市場規模和趨勢

2024年，美國原料藥 CDMO市值為252.8億美元，預計2030年將達到338.6億美元，2025年至2030年期間的複合年成長率為5.1%。這一成長主要源於對先進製藥製造服務日益成長的需求，這些服務旨在支持創新藥物和治療方法的開發。此外，對生技藥品和高效價API的投資不斷增加也推動了市場擴張。慢性病的流行以及對高效、可擴展生產解決方案日益成長的需求也促進了市場的發展。

這一市場成長背後的關鍵驅動力包括製程化學和製造自動化領域的技術進步，這些進步能夠提高產量比率、消除浪費並提升產品品質。鼓勵外包給專業CDMO的監管支援至關重要，因為這些組織有助於確保遵守嚴格的FDA和國際標準。個人化醫療和新型療法日益受到關注，導致對小規模、複雜原料藥製造的需求不斷成長，而CDMO憑藉其靈活性和專業知識在這一領域表現出色。製藥公司與CDMO之間合作的加強也促進了創新，使公司能夠透過縮短上市時間來更好地滿足患者不斷變化的需求。

這個市場蘊含著巨大的機會，尤其是在生技藥品、基因療法和細胞療法的開發領域，這些領域需要高度專業的原料藥生產。連續生產和流動化學的趨勢為CDMO提供了一條途徑，使其能夠提高效率和可擴展性，同時降低成本和環境影響。

目錄

第1章調查方法與範圍

第2章執行摘要

第 3 章美國原料藥CDMO 市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 產業挑戰
  • 產業分析工具
    • 波特分析
    • PESTEL分析

第4章美國原料藥CDMO 市場：依產品估算與趨勢分析

  • 美國原料藥CDMO 市場（按產品分類）：關鍵要點
  • 2024 年及 2030 年產品趨勢分析及市場佔有率
  • 按產品，2018-2030
    • 傳統活性藥物成分
    • 高效活性藥物成分
    • 抗體-藥物偶聯物（ADC）
    • 其他

第5章美國原料藥CDMO 市場：綜合、估算與趨勢分析

  • 美國原料藥CDMO 市場（按合成）: 關鍵要點
  • 2024 年及 2030 年綜合趨勢分析及市場佔有率
  • 按成分分類，2018-2030 年
    • 合成
    • 生物技術

第6章美國原料藥CDMO 市場：按藥物的估計和趨勢分析

  • 美國原料藥CDMO 市場（按藥品類別）：關鍵要點
  • 2024 年及 2030 年藥物趨勢分析及市場佔有率
  • 依藥物分類，2018-2030 年
    • 創新的
    • 非專利的

第7章美國原料藥CDMO 市場：依工作流程估算與趨勢分析

  • 美國原料藥CDMO 市場（按工作流程）：關鍵要點
  • 2024 年及 2030 年工作流程趨勢分析及市場佔有率
  • 按工作流程，2018-2030
    • 臨床
    • 商業的

第 8 章美國原料藥CDMO 市場：按應用估算和趨勢分析

  • 美國原料藥CDMO 市場（按應用）：關鍵要點
  • 2024年及2030年應用變化分析及市場佔有率
  • 按應用，2018-2030 年
    • 腫瘤學
    • 荷爾蒙
    • 青光眼
    • 心血管疾病
    • 糖尿病
    • 其他

第9章 競爭態勢

  • 公司分類
  • 公司市場定位
  • 公司熱圖分析
  • 公司簡介/上市公司
    • Thermo Fisher Scientific Inc.
    • Novo Group（Catalent, Inc.）
    • Cambrex Corporation
    • Piramal Pharma Limited
    • Corden Pharma
    • Siegfried Holding AG
    • Seqens North America
    • SK pharmteco Inc.
    • Noramco.
    • BSP Pharmaceuticals
Product Code: GVR-4-68040-629-9

Market Size & Trends:

The U.S. active pharmaceutical ingredients CDMO market was valued at USD 25.28 billion in 2024 and is projected to reach USD 33.86 billion by 2030, growing at a CAGR of 5.1% from 2025 to 2030. This growth is driven by rising demand for advanced pharmaceutical manufacturing services to support the development of innovative drugs and therapies. In addition, increasing investments in biologics and high-potency APIs drive market expansion. The growing prevalence of chronic diseases and the need for efficient, scalable production solutions also contribute to the market's momentum.

Key drivers supporting this market growth include technological advancements in process chemistry and manufacturing automation, which improve yield, reduce waste, and enhance product quality. Regulatory support encouraging outsourcing to specialized CDMOs is vital, as these organizations help ensure compliance with stringent FDA and international standards. The increasing focus on personalized medicine and novel therapies drives demand for small-batch, complex API manufacturing, areas where CDMOs excel due to their flexibility and expertise. Growing collaborations between pharmaceutical firms and CDMOs also foster innovation and accelerate time-to-market, enabling companies to meet better evolving patient better needs.

The market presents significant opportunities, especially in developing biologics, gene therapies, and cell therapies requiring highly specialized API manufacturing. The trend toward continuous manufacturing and flow chemistry offers avenues for CDMOs to improve efficiency and scalability while reducing costs and environmental impact.

U.S. Active Pharmaceutical Ingredients CDMO Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. active pharmaceutical ingredients CDMO market report based on product, synthesis, drug, workflow, and application.

  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Traditional Active Pharmaceutical Ingredient
  • Highly Potent Active Pharmaceutical Ingredient
  • Antibody Drug Conjugate (ADC)
  • Other
  • Synthesis Outlook (Revenue, USD Million, 2018 - 2030)
  • Synthetic
  • Biotech
  • Drug Outlook (Revenue, USD Million, 2018 - 2030)
  • Innovative
  • Generic
  • Workflow Outlook (Revenue, USD Million, 2018 - 2030)
  • Clinical
  • Commercial
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Oncology
  • Hormonal
  • Glaucoma
  • Cardiovascular disease
  • Diabetes
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources and Third-Party Perspectives
    • 1.3.4. Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation and Data Visualization
  • 1.6. Data Validation and Publishing

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Active Pharmaceutical Ingredients CDMO Market Variables, Trends and Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Industry Challenge
  • 3.3. Industry Analysis Tools
    • 3.3.1. PORTER's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and social landscape
      • 3.3.2.3. Technological landscape

Chapter 4. U.S. Active Pharmaceutical Ingredients CDMO Market: Product Estimates and Trend Analysis

  • 4.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Product: Key Takeaways
  • 4.2. Product Movement Analysis and Market Share, 2024 and 2030
  • 4.3. Market Estimates and Forecasts, By Product, 2018 - 2030 (USD Million)
    • 4.3.1. Traditional Active Pharmaceutical Ingredient
      • 4.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Highly Potent Active Pharmaceutical Ingredient
      • 4.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Antibody Drug Conjugate (ADC)
      • 4.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Other
      • 4.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Active Pharmaceutical Ingredients CDMO Market: Synthesis Estimates and Trend Analysis

  • 5.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Synthesis: Key Takeaways
  • 5.2. Synthesis Movement Analysis and Market Share, 2024 and 2030
  • 5.3. Market Estimates and Forecasts, By Synthesis, 2018 - 2030 (USD Million)
    • 5.3.1. Synthetic
      • 5.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. Biotech
      • 5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Active Pharmaceutical Ingredients CDMO Market: Drug Estimates and Trend Analysis

  • 6.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Drug: Key Takeaways
  • 6.2. Drug Movement Analysis and Market Share, 2024 and 2030
  • 6.3. Market Estimates and Forecasts, By Drug, 2018 - 2030 (USD Million)
    • 6.3.1. Innovative
      • 6.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Generic
      • 6.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Active Pharmaceutical Ingredients CDMO Market: Workflow Estimates and Trend Analysis

  • 7.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Workflow: Key Takeaways
  • 7.2. Workflow Movement Analysis and Market Share, 2024 and 2030
  • 7.3. Market Estimates and Forecasts, By Workflow, 2018 - 2030 (USD Million)
    • 7.3.1. Clinical
      • 7.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Commercial
      • 7.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Active Pharmaceutical Ingredients CDMO Market: Application Estimates and Trend Analysis

  • 8.1. U.S. Active Pharmaceutical Ingredients CDMO Market, By Application: Key Takeaways
  • 8.2. Application Movement Analysis and Market Share, 2024 and 2030
  • 8.3. Market Estimates and Forecasts, By Application, 2018 - 2030 (USD Million)
    • 8.3.1. Oncology
      • 8.3.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. Hormonal
      • 8.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Glaucoma
      • 8.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. Cardiovascular disease
      • 8.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Diabetes
      • 8.3.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Others
      • 8.3.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Positioning
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles/Listing
    • 9.4.1. Thermo Fisher Scientific Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Portfolio
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Novo Group (Catalent, Inc.)
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Portfolio
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. Cambrex Corporation
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Portfolio
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Piramal Pharma Limited
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Portfolio
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Corden Pharma
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Portfolio
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Siegfried Holding AG
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Portfolio
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. Seqens North America
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Portfolio
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. SK pharmteco Inc.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Portfolio
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Noramco.
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Portfolio
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. BSP Pharmaceuticals
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Portfolio
      • 9.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S active pharmaceutical ingredients CDMO market: key market driver analysis
  • Table 3 U.S active pharmaceutical ingredients CDMO market: Key market restraint analysis
  • Table 4 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by product (USD Million)
  • Table 5 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by synthesis (USD Million)
  • Table 6 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by drug (USD Million)
  • Table 7 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by workflow (USD Million)
  • Table 8 U.S active pharmaceutical ingredients CDMO market estimates and forecast, by application (USD Million)
  • Table 9 Recent developments and impact analysis by key market participants
  • Table 10 Company heat map analysis, 2024
  • Table 11 Companies implementing key strategies

List of Figures

  • Fig. 1 U.S active pharmaceutical ingredients CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing and forecasting
  • Fig. 7 Parent market analysis
  • Fig. 8 Market formulation and validation
  • Fig. 9 U.S active pharmaceutical ingredients CDMO market snapshot
  • Fig. 10 U.S active pharmaceutical ingredients CDMO market segment snapshot
  • Fig. 11 U.S active pharmaceutical ingredients CDMO market competitive landscape snapshot
  • Fig. 12 Market research process
  • Fig. 13 Market driver relevance analysis (Current and future impact)
  • Fig. 14 Market restraint relevance analysis (Current and future impact)
  • Fig. 15 U.S active pharmaceutical ingredients CDMO market: Product outlook key takeaways (USD Million)
  • Fig. 16 U.S active pharmaceutical ingredients CDMO market: Product movement analysis 2024 & 2030 (USD Million)
  • Fig. 17 Traditional Active Pharmaceutical Ingredient market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Highly Potent Active Pharmaceutical Ingredient market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Antibody Drug Conjugate (ADC)s market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Others market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 U.S active pharmaceutical ingredients CDMO market: Synthesis outlook key takeaways (USD Million)
  • Fig. 22 U.S active pharmaceutical ingredients CDMO market: Synthesis movement analysis 2024 & 2030 (USD Million)
  • Fig. 23 Synthetic market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Biotech market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S active pharmaceutical ingredients CDMO market: Drug outlook key takeaways (USD Million)
  • Fig. 26 U.S active pharmaceutical ingredients CDMO market: Drug movement analysis 2024 & 2030 (USD Million)
  • Fig. 27 Innovative market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Generics market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Distributed recipient drugs market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 U.S active pharmaceutical ingredients CDMO market: Workflow outlook key takeaways (USD Million)
  • Fig. 31 U.S active pharmaceutical ingredients CDMO market: Workflow movement analysis 2024 & 2030 (USD Million)
  • Fig. 32 Clinical market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Commercial market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 U.S active pharmaceutical ingredients CDMO market: Application outlook key takeaways (USD Million)
  • Fig. 35 U.S active pharmaceutical ingredients CDMO market: Application movement analysis 2024 & 2030 (USD Million)
  • Fig. 36 Oncology market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Hormonal market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Glaucoma market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Cardiovascular disease market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Diabetes market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates & forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Strategy framework
  • Fig. 43 Company categorization